Asia Pacific is not one uniform scientific or clinical market. TASCAP uses an A to Z country order to present four complementary capability clusters without implying a hierarchy.
Australia contributes frontier biotechnology natural bioactive discovery and translational research. China including Hong Kong Macao and Taiwan contributes multi-omics scale research infrastructure and extracellular-vesicle manufacturing capability. Japan contributes advanced regenerative medicine refined medical aesthetics and mature service delivery. Singapore contributes sports medicine modern clinical management and precision-health technology.
The value of a regional consortium lies in making methods evidence definitions and responsibility transferable while respecting local professional standards regulation and patient expectations.
Back to News Centre